Pirfenidone added to standard therapy for myocardial infarction further reduces left ventricular fibrosis: a preclinical study

Back

HFA Premium Access

Pirfenidone added to standard therapy for myocardial infarction further reduces left ventricular fibrosis: a preclinical study

Session: From mechanisms to targets over the heart failure spectrum

Topic: Heart Failure

Speaker: Doctor A. Aimo (Pisa, IT)

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Doctor Alberto Aimo

Sant'Anna School of Advanced Studies, Pisa (Italy)

4 presentations

0 follower

5 more presentations in this session

ATPIF-1 regulates the cardiac mitochondrial permeability transition pore and mitochondrial shape in mice

Speaker: Mr P. Sanchez (Groningen, NL)

Access

Abstract

Slides

Effect of different post-myocardial infarction exercise training modality on cardiac calcium sensitivity and function

Speaker: Professor J. Zhang (San Antonio, US)

Access

Abstract

Slides

The ketone body 3-hydroxybutyrate increases cardiac output through afterload reduction and not through increased left ventricular contractility

Speaker: Doctor N. Gopalasingam (Aarhus, DK)

Access

Abstract

Slides

Endoplasmic reticulum stress as a therapeutic target for the treatment of cardiac and renal damage post myocardial infarction in the context of obesity

Speaker: Miss B. Delgado Valero (Madrid, ES)

Access

Abstract

Slides

Pressure overload-induced cardiac hypertrophy stimulates tumour growth in tumour prone apc-min mice

Speaker: Ms S. De Wit (Groningen, NL)

Access

Abstract

Slides

Access the full session

From mechanisms to targets over the heart failure spectrum

Speakers: Doctor A. Aimo, Mr P. Sanchez, Professor J. Zhang, Doctor N. Gopalasingam, Miss B. Delgado Valero...

Access

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources